Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    115

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,633.23204.33-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,524.4537.68-0.15%
NASDAQ21,145.4833.11-0.16%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,936.4125.670.20%
S&P 5006,376.7213.05-0.20%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers